{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 42,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 13,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/7",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.401,
        "w": 0.209,
        "x": 0.099,
        "y": 0.409
      },
      "kind": "chart",
      "text": "Ophthalmic Pharmaceuticals 17%\nSurgical 20%\nVision Care 63%",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e89de337-3bd1-4a02-b5b0-4ca5c0f2943c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.159,
        "w": 0.229,
        "x": 0.099,
        "y": 0.218
      },
      "kind": "list",
      "text": "Bausch + Lomb\n+1% 2Q22 Reported Revenue\n+6% 2Q22 Organic Revenue1,2\n+6% 2Q22 Constant Currency¹",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52173f45-3e55-4d4b-ba8c-55dab1a300d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.209,
        "x": 0.795,
        "y": 0.218
      },
      "kind": "list",
      "text": "Expanding Into New Product Categories\nRevive™ CUSTOM SOFT CONTACT LENSES new family of customizable soft contact lenses designed to meet needs of more patients\n~18M Americans diagnosed with dry eye disease (DED) 3,4\nSubmitted NOV03 NDA to FDA in June",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "baf05ee3-8fa3-4f9d-af20-f990d5abe345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.209,
        "x": 0.57,
        "y": 0.218
      },
      "kind": "list",
      "text": "Investing in Categories Growing Faster Than Market\n+21% reported revenue growth in Lumify®; early stages of brand expansion with an opportunity to enter adjacent categories\n+50% reported revenue growth for SiHy dailies\nGlobal SiHy market growing at a ~11% CAGR6",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c22cb82c-ccd0-43c7-bf58-81f43eb263db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.209,
        "x": 0.345,
        "y": 0.218
      },
      "kind": "list",
      "text": "Continued Momentum in Key Portfolios\n~410bps increase in U.S. market share (dollar) in 2Q22 vs. 2Q21 for Bausch + Lomb eye vitamin franchise5\n+39% reported revenue growth in BioTrue® Solutions Franchise; global mega brand, expanding with two new launches underway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dca7ccf5-5feb-4193-ab29-544313c777d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.693,
        "x": 0.155,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations\n3. Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy and Dry Eye Disease. Ocular immunology and inflammation, 29(6), 1168-1176. https://doi.org/10.1080/09273948.2020.1841804.\n4. 2020 Dry Eye Products Market Report: A Global Analysis for 2019 to 2025. Market Scope. Retrieved from https://www.market-scope.com/pages/reports/250/2020-ophthalmic-landscape-report-global-analysis-for-2019-to-2025-april-2021#reports.\n5. B+L Consumer Data Science, Data Source: IRI, Total US Panel, Omnichannel Data Ending 06-26-22.\n6. CAGR years include 2019-2030. 2019-2021 actuals are from industry sources. 2022 onwards is internal estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2466d033-312e-4fd5-8229-0342373f0590",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.26,
        "x": 0.045,
        "y": 0.045
      },
      "kind": "title",
      "text": "2Q22 Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bb606f4-951c-4d1b-ae74-b79f61f6ed29",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "3a4eeba5-fc3d-47a3-8ac8-d6e98f6b3c1f",
      "evidence": "chart/pie: Ophthalmic Pharmaceuticals 17%",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 5,
      "beatId": "663de2ed-ef0d-4bcb-910f-3eb01f803a43",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 5-7 discuss the company's overview and key messages",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0820f93-74dc-4006-a0cc-2e2499a07167",
      "evidence": "The loop opens on slide 6 and closes on slide 15, showcasing the company's opportunities",
      "position": 0,
      "objective": "Highlighting the benefits of a standalone Bausch + Lomb",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}